Plain Language vs Standard Format for Youth Understanding of COVID-19 Recommendations: A Randomized Clinical Trial.
Journal
JAMA pediatrics
ISSN: 2168-6211
Titre abrégé: JAMA Pediatr
Pays: United States
ID NLM: 101589544
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
pmc-release:
07
08
2024
medline:
6
9
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
To ensure that youths can make informed decisions about their health, it is important that health recommendations be presented for understanding by youths. To compare understanding, accessibility, usability, satisfaction, intention to implement, and preference of youths provided with a digital plain language recommendation (PLR) format vs the original standard language version (SLV) of a health recommendation. This pragmatic, allocation-concealed, blinded, superiority randomized clinical trial included individuals from any country who were 15 to 24 years of age, had internet access, and could read and understand English. The trial was conducted from May 27 to July 6, 2022, and included a qualitative component. An online platform was used to randomize youths in a 1:1 ratio to an optimized digital PLR or SLV format of 1 of 2 health recommendations related to the COVID-19 vaccine; youth-friendly PLRs were developed in collaboration with youth partners and advisors. The primary outcome was understanding, measured as the proportion of correct responses to 7 comprehension questions. Secondary outcomes were accessibility, usability, satisfaction, preference, and intended behavior. After completion of the survey, participants indicated their interest in completing a 1-on-1 semistructured interview to reflect on their preferred digital format (PLR or SLV) and their outcome assessment survey response. Of the 268 participants included in the final analysis, 137 were in the PLR group (48.4% female) and 131 were in the SLV group (53.4% female). Most participants (233 [86.9%]) were from North and South America. No significant difference was found in understanding scores between the PLR and SLV groups (mean difference, 5.2%; 95% CI, -1.2% to 11.6%; P = .11). Participants found the PLR to be more accessible and usable (mean difference, 0.34; 95% CI, 0.05-0.63) and satisfying (mean difference, 0.39; 95% CI, 0.06-0.73) and had a stronger preference toward the PLR (mean difference, 4.8; 95% CI, 4.5-5.1 [4.0 indicated a neutral response]) compared with the SLV. No significant difference was found in intended behavior (mean difference, 0.22 (95% CI, -0.20 to 0.74). Interviewees (n = 14) agreed that the PLR was easier to understand and generated constructive feedback to further improve the digital PLR. In this randomized clinical trial, compared with the SLV, the PLR did not produce statistically significant findings in terms of understanding scores. Youths ranked it higher in terms of accessibility, usability, and satisfaction, suggesting that the PLR may be preferred for communicating health recommendations to youths. The interviews provided suggestions for further improving PLR formats. ClinicalTrials.gov Identifier: NCT05358990.
Identifiants
pubmed: 37548983
pii: 2808109
doi: 10.1001/jamapediatrics.2023.2686
pmc: PMC10407760
doi:
Substances chimiques
COVID-19 Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT05358990']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
956-965Subventions
Organisme : CIHR
ID : GA3-177732
Pays : Canada
Organisme : CIHR
ID : FRN VR4-172741
Pays : Canada
Organisme : CIHR
ID : REC 183153
Pays : Canada
Investigateurs
Lisa Stallwood
(L)
Adrian Sammy
(A)
Matthew Prebeg
(M)
Jacqueline Relihan
(J)
Ami Baba
(A)
Rana Charide
(R)
Shahab Sayfi
(S)
Sarah A Elliott
(SA)
Lisa Hartling
(L)
Matthew Munan
(M)
Dawn P Richards
(DP)
Joseph L Mathew
(JL)
Tamara Kredo
(T)
Lawrence Mbuagbaw
(L)
Ashley Motilall
(A)
Shannon D Scott
(SD)
Miloslav Klugar
(M)
Tamara Lotfi
(T)
Adrienne L Stevens
(AL)
Kevin Pottie
(K)
Holger J Schünemann
(HJ)
Nancy J Butcher
(NJ)
Martin Offringa
(M)
Elie A Akl
(EA)
Jozef Suvada
(J)
Maicon Falavigna
(M)
Références
Qual Saf Health Care. 2005 Oct;14(5):367-70
pubmed: 16195572
Med Care. 2004 Nov;42(11):1132-42
pubmed: 15586841
Trials. 2015 Apr 16;16:164
pubmed: 25873338
J Clin Epidemiol. 2010 Jun;63(6):620-6
pubmed: 20434024
Trials. 2023 Jan 14;24(1):27
pubmed: 36641457
Med Decis Making. 2016 Aug;36(6):692-702
pubmed: 27091380
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Health Res Policy Syst. 2018 May 29;16(1):45
pubmed: 29843743
J Clin Epidemiol. 2023 Feb;154:125-135
pubmed: 36503004
Med Decis Making. 2010 Sep-Oct;30(5):566-77
pubmed: 20643912
BMC Health Serv Res. 2014 Jul 27;14:321
pubmed: 25064372
J Med Internet Res. 2009 Apr 03;11(2):e9
pubmed: 19403465
JAMA. 2022 Dec 13;328(22):2252-2264
pubmed: 36511921
BMJ. 2016 Jun 28;353:i2016
pubmed: 27353417
J Clin Epidemiol. 2022 Jan;141:18-25
pubmed: 34534671
J Clin Epidemiol. 2016 Jun;74:7-18
pubmed: 26791430
BMJ. 2010 Mar 23;340:c332
pubmed: 20332509
J Clin Epidemiol. 2021 Jul;135:182-186
pubmed: 33836255
MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1344-1348
pubmed: 34555007
J Clin Epidemiol. 2015 Feb;68(2):182-90
pubmed: 25034199
Int J Technol Assess Health Care. 2017 Jan;33(2):176-182
pubmed: 28655365
J Clin Epidemiol. 2012 Jul;65(7):748-55
pubmed: 22564503
J Clin Epidemiol. 2014 Jul;67(7):769-72
pubmed: 24560088
J Clin Epidemiol. 2022 Aug;148:104-114
pubmed: 35500815
BMC Health Serv Res. 2016 Feb 02;16:37
pubmed: 26837683
PLOS Glob Public Health. 2022 Oct 14;2(10):e0001166
pubmed: 36962671
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
J Man Manip Ther. 2019 May;27(2):63-65
pubmed: 30935322